Response to “A critical perspective on patient activation through integrative healthcare counselling in oncology”, based on the “CCC-Integrativ” study

References

[1] Valentini J, Froehlich D, Roesel I, Stolz R, Mahler C, Martus P, Klafke N, Horneber M, Witte C, Kramer K, Greil C, Gruen B, Tomaschko-Ubelaender K, Joos S. Enhancing patient activation: a controlled implementation study of an interprofessional evidence-based counseling program for complementary and integrative healthcare in cancer patients (‘CCC-Integrativ’). Front Med 2024; 18(6): 1013–1025

[2] Valentini J, Fröhlich D, Stolz R, Mahler C, Martus P, Klafke N, Horneber M, Frasch J, Kramer K, Bertz H, Grün B, Tomaschko-Ubeländer K, Joos S. Interprofessional evidence-based counselling programme for complementary and integrative healthcare in patients with cancer: study protocol for the controlled implementation study CCC-Integrativ. BMJ Open 2022; 12(2): e055076

[3] Wright A, Hannon J, Hegedus EJ, Kavchak AE. Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Manual Manip Ther 2012; 20(3): 160–166

[4] Ganju J. Why “minimal clinically important difference” for interpreting the magnitude of the treatment effect is not useful. Pharm Stat 2025; 24(3): e70015

[5] Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood) 2013; 32(2): 207–214

[6] Krouse RS, Grant M, McCorkle R, Wendel CS, Cobb MD, Tallman NJ, Ercolano E, Sun V, Hibbard JH, Hornbrook MC. A chronic care ostomy self-management program for cancer survivors. Psychooncology 2016; 25(5): 574–581

[7] Lemanska A, Poole K, Manders R, Marshall J, Nazar Z, Noble K, Saxton JM, Turner L, Warner G, Griffin BA, Faithfull S. Patient activation and patient-reported outcomes of men from a community pharmacy lifestyle intervention after prostate cancer treatment. Support Care Cancer 2022; 30(1): 347–358

[8] Soumerai SB, Ceccarelli R, Koppel R. False dichotomies and health policy research designs: randomized trials are not always the answer. J Gen Intern Med 2017; 32(2): 204–209

[9] Fernainy P, Cohen AA, Murray E, Losina E, Lamontagne F, Sourial N. Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion. BMC Proc 2024; 18(Suppl 2): 1

[10] Frieden TR. Evidence for health decision making—beyond randomized, controlled trials. N Engl J Med 2017; 377(5): 465–475

[11] D’Egidio V, Sestili C, Mancino M, Sciarra I, Cocchiara R, Backhaus I, Mannocci A, De Luca A, Frusone F, Monti M, La Torre G. Counseling interventions delivered in women with breast cancer to improve health-related quality of life: a systematic review. Qual Life Res 2017; 26(10): 2573–2592

[12] Bossert J, Mahler C, Boltenhagen U, Kaltenbach A, Froehlich D, Szecsenyi J, Wensing M, Joos S, Klafke N. Protocol for the process evaluation of a counselling intervention designed to educate cancer patients on complementary and integrative health care and promote interprofessional collaboration in this area (the CCC-Integrativ study). PLoS One 2022; 17(5): e0268091

[13] Dürsch H, Boltenhagen U, Mahler C, Joos S, Joachim S, Klafke N. A qualitative investigation of factors influencing the integration of complementary and integrative healthcare recommendations in the daily lives of patients with cancer. Integr Cancer Ther 2024; 23: 15347354241252195

[14] Dürsch H, Boltenhagen U, Mahler C, Joos S, Szecsenyi J, Klafke N. A qualitative analysis of cancer patients’ perceptions of an interprofessional counseling service on complementary and integrative healthcare. Qual Health Res 2024; 34(12): 1132–1146

[15] Klafke N, Bossert J, Boltenhagen U, Froehlich D, Mahler C, Joos S, Wensing M. Counseling lifestyle medicine in oncology: a qualitative analysis of interprofessional patient-nurse-physician interactions. Patient Educ Couns 2024; 127: 108352

[16] LeitlinienprogrammOnkologie. (Deutsche Krebsgesellschaft, D. K., AWMF) S3-Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen, Langversion 2.0, 2024, AWMF-Registernummer: 032–055OL. 2024. Available at https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/

[17] Harvey L, Fowles JB, Xi M, Terry P. When activation changes, what else changes? The relationship between change in patient activation measure (PAM) and employees’ health status and health behaviors. Patient Educ Couns 2012; 88(2): 338–343

[18] Carroll C, Patterson M, Wood S, Booth A, Rick J, Balain S. A conceptual framework for implementation fidelity. Implement Sci 2007; 2(1): 40

[19] Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res 2005; 40(6 Pt 1): 1918–1930

RIGHTS & PERMISSIONS

Higher Education Press